0000000000223773

AUTHOR

A. Lopez

Measurement of charmed-particle lifetimes and decay branching ratios

The lifetimes of charmed hadrons photoproduced in nuclear emulsion have been computed from a practically background-free sample of 44 neutral particle decays and 42 charged-particle decays including 27D±, 11Λc+, 1Ds+ and 3 ambiguous decays. The values obtained are τ(D0, bar D0) = (3.6-0.8+1.2 ± 0.7) 10-13 s, τ(D±) = (5.0-1.0+1.5 ± 1.9) 10-13 s, τ(Λc+) = = (2.3-0.6+0.9 ± 0.4) 10-13 s. Branching ratios of various decay topologies were also obtained.

research product

Search for the t and b' quarks in hadronic decays of the Z0 boson

We present a search for the third generation up type quark t and a possible fourth down type quark b' in hadronic Z0 decays observed in DELPHI at the LEP collider. For any scenario with a decay through the charged current or into a charged Higgs with a mass at least 6 GeV/c2 below the t and 3 GeVc2 below the b' mass, we set a lower limit for the t quark mass at 44.0 GeV/c2 and for the b' mass at 44.5 GeV/c2. For specific scenarios the mass limits are slightly higher, e.g. for charged current decays the limits are 44.5 and 45.0 GeV/c2 respectively, where all limits are given at a 95% confidence level. © 1990.

research product

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

Abstract Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in su…

research product

Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

It has come to our attention that the name of one of the authors in our manuscript was incorrectly spelled ‘Jinyoung Byan’; the correct spelling is ‘Jinyoung Byun’ as in the author list above. In addition, the excel files of the supplementary tables were not included during the online publication of our article. These have now been made available online. We apologize for any inconvenience caused.

research product

Sonographische Diagnose eines Holoakardius

In the 28th week of gestation a normal foetus and a holoacardius were diagnosed via sonography in a biamnotic monochoriatic twin pregnancy. The growth of the foetuses was observed under continuous sonographic control up to the 40th week of pregnancy. The patient delivered a healthy twin by Caesarean section and the acardius was subjected to a postmortem. Macroscopic and histological findings in the foetus, the placenta and the umbilical cords are demonstrated. The pathogenesis of the holoacardius is discussed as being due to chromosomal aberrations and foeto-foetal transfusion syndrome.

research product

Sensitivity of the Cherenkov Telescope Array for probing cosmology and fundamental physics with gamma-ray propagation

Full list of authors: Abdalla, H.; Abe, H.; Acero, F.; Acharyya, A.; Adam, R.; Agudo, I; Aguirre-Santaella, A.; Alfaro, R.; Alfaro, J.; Alispach, C.; Aloisio, R.; Batista, R. Alves; Amati, L.; Amato, E.; Ambrosi, G.; Anguner, E. O.; Araudo, A.; Armstrong, T.; Arqueros, F.; Arrabito, L.; Asano, K.; Ascasibar, Y.; Ashley, M.; Backes, M.; Balazs, C.; Balbo, M.; Balmaverde, B.; Baquero Larriva, A.; Martins, V. Barbosa; Barkov, M.; Baroncelli, L.; de Almeida, U. Barres; Barrio, J. A.; Batista, P-, I; Becerra Gonzalez, J.; Becherini, Y.; Beck, G.; Tjus, J. Becker; Belmont, R.; Benbow, W.; Bernardini, E.; Berti, A.; Berton, M.; Bertucci, B.; Beshley, V; Bi, B.; Biasuzzi, B.; Biland, A.; Bissaldi, …

research product

Search forBs0→μ+μ−andB0→μ+μ−Decays with CDF II

A search has been performed for B{sub s}{sup 0} {yields} {mu}{sup +}{mu}{sup -} and B{sup 0} {yields} {mu}{sup +}{mu}{sup -} decays using 7 fb{sup -1} of integrated luminosity collected by the CDF II detector at the Fermilab Tevatron collider. The observed number of B{sup 0} candidates is consistent with background-only expectations and yields an upper limit on the branching fraction of {Beta}(B{sup 0} {yields} {mu}{sup +}{mu}{sup -}) < 6.0 x 10{sup -9} at 95% confidence level. We observe an excess of B{sub s}{sup 0} candidates. The probability that the background processes alone could produce such an excess or larger is 0.27%. The probability that the combination of background and the expe…

research product

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RECORD-2

ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…

research product

Search for pair production of neutral Higgs bosons in Z$^0$ decays

The pair production of the lightest scalar Higgs boson, h, and a pseudoscalar Higgs boson, A, was searched for in a data sample containing 10 000 hadronic Z0 decays. The search involved both leptonic and purely hadronic decay channels of each Higgs boson. No signal was found, and limits on the Higgs boson masses, in the framework of the minimal supersymmetric extension of the standard model, ar reported up to 35 GeV/c2 at 95% CL, for both tan β > 1 and tan β < 1, where tan β is the ratio of the vacuum expectation values of the two Higgs doublets.

research product

Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study

&lt;b&gt;&lt;i&gt;Objective:&lt;/i&gt;&lt;/b&gt; Older people approaching the end of life are at a high risk for adverse drug reactions. Approaching the end of life should change the therapeutic aims, triggering a reduction in the number of drugs.&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;The main aim of this study is to describe the preventive and symptomatic drug treatments prescribed to patients discharged with a limited life expectancy from internal medicine and geriatric wards. The secondary aim was to describe the potentially severe drug-drug interactions (DDI). &lt;b&gt;&lt;i&gt;Materials and Methods:&lt;/i&gt;&lt;/b&gt; We analyzed Registry of Polytherapies Societa Italiana di Medicina I…

research product

Sensitivity of the Cherenkov Telescope Array to a dark matter signal from the Galactic centre

Full list of authors: Acharyya, A.; Adam, R.; Adams, C.; Agudo, I.; Aguirre-Santaella, A.; Alfaro, R.; Alfaro, J.; Alispach, C.; Aloisio, R.; Alves Batista, R.; Amati, L.; Ambrosi, G.; Angüner, E. O.; Antonelli, L. A.; Aramo, C.; Araudo, A.; Armstrong, T.; Arqueros, F.; Asano, K.; Ascasíbar, Y. Ashley, M.; Balazs, C.; Ballester, O.; Baquero Larriva, A.; Barbosa Martins, V.; Barkov, M.; Barres de Almeida, U.; Barrio, J. A.; Bastieri, D.; Becerra, J.; Beck, G.; Becker Tjus, J.; Benbow, W.; Benito, M.; Berge, D.; Bernardini, E.; Bernlöhr, K.; Berti, A.; Bertucci, B.; Beshley, V.; Biasuzzi, B.; Biland, A.; Bissaldi, E.; Biteau, J.; Blanch, O.; Blazek, J.; Bocchino, F.; Boisson, C.; Bonneau Arbe…

research product

Cross sections and some features of charm photoproduction at gamma energies of 20-70 GeV

Abstract We report some results on charm photoproduction at γ energies ranging from 20 to 70 GeV. 36 events with pairs of charmed particles have been found in emulsions. The computed total cross section is (230±57)nb/nucleon. Frequencies of different production channels and some distributions are presented and compared with the predictions from a photon-gluon fusion model with string fragmentation.

research product